Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer

This is the first report that the combination of paclitaxel and cisplatin i s feasible in a patient with recurrent ovarian cancer undergoing hemodialys is, Paclitaxel at a dose of 150 mg/m(2) was administered as a 3-h continuou s i.v. infusion. Thirty minutes after paclitaxel administration, cisplatin was administered at a dose of 30 mg/m(2) for 30 min. Hemodialysis was start ed 30 min after completion of the cisplatin infusion and performed for 5 h. The maximum plasma concentrations of paclitaxel, total platinum and free p latinum were 3.26, 2.44 and 1.84 mug/ml, respectively. The AUC of paclitaxe l and free platinum were 15.3 end 1.76 mug . h/ml, respectively. The pelvic tumor size was reduced by 42% on MRI after the second course of this thera py. Grade IV neutropenia and grade III thrombopenia were observed, We concl ude that paclitaxel and cisplatin combination chemotherapy is efficacious a nd feasible for an ovarian cancer patient under hemodialysis. [(C) 2001 Lip pincott Williams & Wilkins.].